Artificial intelligence, machine learning, and drug repurposing in cancer
Ziaurrehman Tanoli, Markus Vähä‐Koskela, Tero Aittokallio
Abstract
: The scarcity of clinical patient data and the current focus on genetic aberrations as primary drug targets may limit the performance of anticancer drug repurposing approaches that rely solely on genomics-based information. Functional testing of cancer patient cells exposed to a large number of targeted therapies and their combinations provides an additional source of repurposing information for tissue-aware AI approaches.
Topics & Concepts
RepurposingDrug repositioningComputer scienceArtificial intelligenceIdentification (biology)Drug discoveryDrug developmentMachine learningDrugMedicineBioinformaticsPharmacologyBiologyEcologyBotanyComputational Drug Discovery MethodsBiosimilars and Bioanalytical Methodsvaccines and immunoinformatics approaches